Cutaneous T-Cell Lymphoma Treatment: Case Series of Combination Therapy With Intralesional Injections of 5-Fluorouracil and Topical Imiquimod. 

 -  2023 
<br/><br/>Available online through MWHC library: 2000 - 2010, Available in print through MWHC library: July 1998 - 2007 
<br/><br/> Cutaneous T-cell lymphoma (CTCL) is a chronic form of skin cancer. Skin-directed therapies rarely achieve complete clearance of lesions, and recurrences are frequent. In this case series, 9 patients with stage IA to IVA2 CTCL received intralesional (IL) therapy with 5-fluorouracil (5-FU) and imiquimod (IMQ) cream 5% daily to recalcitrant plaques and tumors. All 9 patients attained a complete response (CR) with no recurrences reported and no severe side effects. We find that combination IL 5-FU and IMQ cream 5% daily is a well-tolerated, effective, and durable skin-directed therapy for recalcitrant plaques and tumors in CTCL. 
<br/><br/><br/>English 
<br/><br/><label>ISSN: </label>0011-4162 
<br/><br/><label>Standard No.: </label>10.12788/cutis.0697 [doi] cutis.0697 [pii] 
<br/><br/><label>Subjects--Topical Terms: </label><br/>*Lymphoma, T-Cell, Cutaneous<br/>*Skin Neoplasms<br/>Fluorouracil<br/>Humans<br/>Imiquimod/tu [Therapeutic Use]<br/>Injections, Intralesional<br/>Lymphoma, T-Cell, Cutaneous/dt [Drug Therapy]<br/>Skin Neoplasms/pa [Pathology]
<br/><br/><label>Subjects--Geographic Terms: </label><br/>MedStar Washington Hospital Center
<br/><br/><label>Index Terms--Occupation: </label><br/>Dermatology<br/>Medical Dermatology Residency
<br/><br/><label>Index Terms--Function: </label><br/>Journal Article